Application of sFlt-1 for the prevention of advanced atherosclerosis in chronic kidney disease

慢性肾脏疾病常与晚期动脉粥样硬化相关。我们发现胎盘生长因子（PlGF）及其内源性拮抗剂sFlt-1在这种情况下发挥重要作用。在本研究中，我们研究了sFlt-1和ApoE双敲除小鼠的表现，以及重组sFlt-1给药对ApoE KO肾衰小鼠的影响。我们的研究结果表明，补充提高血浆sFlt-1水平可能是肾功能不全患者晚期动脉粥样硬化的药物干预的候选药物。

Chronic kidney disease is frequently associated with advanced atherosclerosis. We have found that placental growth factor(PlGF) and its endogenous antagonist, sFlt-1, play important role in this setting. In this study, we investigated the manifestation of sFlt-1 and ApoE double knock-out mouse, as well as the effect of recombinant sFlt-1 administration to ApoE KO mice with renal failure. Our results indicate supplemental enhancement of plasma level of sFlt-1 might be a candidate as a pharmacological intervention for advanced atherosclerosis in patients with renal dysfunction.